The effect of physician prescribing patterns based on ESC guidelines on morbidity improvement among heart failure patients

Authors

  • Ema Pristi Yunita Department of Pharmacy, Faculty of Medicine, Universitas Brawijaya
  • Anindhita Dwi Safitri Department of Pharmacy, Faculty of Medicine, Universitas Brawijaya
  • Ardian Rizal Department of Cardiology, General Hospital of Dr. Saiful Anwar

DOI:

https://doi.org/10.12928/pharmaciana.v11i1.16730

Keywords:

Ejection fraction, heart failure, ESC guidelines, physician prescribing patterns

Abstract

Data from Basic Health Research shows the prevalence of heart failure in Indonesia is between 0.1% to 0.3% of the entire Indonesian population. This number is predicted to increase from year to year. Heart failure is a complex syndrome that can cause abnormalities in the structure and function of the heart. Based on the ejection fraction values, there are three types of heart failure, namely HFrEF (EF: < 40%), HFmrEF (EF: 40-49%), and HFpEF (EF: ≥ 50%). Considering that the type of heart failure requiring treatment according to ESC guidelines is only HFrEF, however, this study would also evaluate the effect of physician prescribing patterns on the morbidity of HFmrEF. The recommendations from ESC guidelines to the treatment of HFrEF that can reduce morbidity and mortality are three medication combinations, namely ACE inhibitors/angiotensin receptor blockers, beta-blockers, and aldosterone antagonists. Therefore, this study aims to determine the effect of the suitability of physician prescribing patterns according to ESC guidelines on improving the morbidity of heart failure patients in HFrEF and HFmrEF type. Improvements in morbidity can be seen from the quality of life score and frequency of hospitalization by using questionnaires. The study was conducted in the cardiology outpatient clinic of Dr. Saiful Anwar General Hospital and Islamic Hospital of Aisyiyah in April-May 2019. Subjects who participated in the study were 57 patients. The One-way ANOVA test results showed no significant difference between physician prescribing patterns of quality of life scores on HFrEF (p = 0.944) while the Kruskal Wallis test for the same parameters on HFmrEF also showed insignificant results (p = 0.210). The Kruskal Wallis test results showed no significant difference between the patterns of physician prescribing to the frequency of hospitalization in both HFrEF and HFmrEF (p = 0.260; p = 0.428). The results showed that physician prescribing patterns in accordance with ESC guidelines resulted in the best quality of life scores on HFrEF. The lowest frequency of hospitalization was also shown in HFrEF patients who received treatment according to ESC guidelines.

References

Berliner, D., & Bauersachs, J. (2017). Current drug therapy in chronic heart failure - the new guidelines of the european society of cardiology (ESC). Korean Circulation Journal, 47(5), 543–554. https://doi.org/10.4070/kcj.2017.0030

Bratsos, S. (2019). Efficacy of angiotensin converting enzyme inhibitors and angiotensin receptor-neprilysin inhibitors in the treatment of chronic heart failure: a review of landmark trials. Cureus, 11(1), 1–8. https://doi.org/10.7759/cureus.3913

Brink, E., Persson, L. O., & Karlson, B. W. (2009). Coping with myocardial infarction: Evaluation of a coping questionnaire. Scandinavian Journal of Caring Sciences, 23(4), 792–800. https://doi.org/10.1111/j.1471-6712.2008.00666.x

Burnett, H., Earley, A., Voors, A. A., Senni, M., McMurray, J. J. V., Deschaseaux, C., & Cope, S. (2017). Thirty years of evidence on the efficacy of drug treatments for chronic heart failure with reduced ejection fraction: a network meta-analysis. Circulation Heart Failure, 10, 1–13. https://doi.org/10.1161/CIRCHEARTFAILURE.116.003529

Kehat, I., & Molkentin, J. D. (2010). Molecular pathways underlying cardiac remodeling during pathophysiologic stimulation. Circulation, 122(25), 2727–2735. https://doi.org/10.1161/CIRCULATIONAHA.110.956839

Lee, D. S., Gona, P., Vasan, R. S., Larson, M. G., Benjamin, E. J., Wang, T. J., Tu, J. V., & Levy, D. (2009). Relation of disease etiology and risk factors to heart failure with preserved or reduced ejection fraction: insights from the national heart, lung, and blood institutes’s framingham heart study. Circulation, 119(24), 3070–3077. https://doi.org/10.1161/CIRCULATIONAHA.108.815944.RELATION

Majid, A. (2010). Factors analysis felated to readmission on patient with congestive heart failure in Yogyakarta Hospital year 2010. University of Indonesia.

Martin, N., Manoharan, K., Thomas, J., Davies, C., & Lumbers, R. T. (2018). Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction. Cochrane Database of Systematic Reviews, 2018(6), 1–197. https://doi.org/10.1002/14651858.CD012721.pub2

Mcmurray, J. J. V, Adamopoulos, S., Anker, S. D., Auricchio, A., Bohm, M., Dickstein, K., Falk, V., Filippatos, G., Fonseca, C., Gomez-Sanchez, M. A., Jaarsma, T., Køber, L., Lip, G. Y. H. ., Maggioni, A. Pietro, Parkhomenko, A., Pieske, B. M., Popescu, B. A., Rønnevik, P. K., Rutten, F. H., … Zeiher, A. (2012). ESC Guideines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. European Heart Journal, 33, 1787–1847. https://doi.org/10.1093/eurheartj/ehs104

Ogbemudia, E. J., & Asekhame, J. (2016). Rehospitalization for heart failure in the elderly. Saudi Medical Journal, 37(10), 1144–1147. https://doi.org/10.15537/smj.2016.10.15259

Oshikoya, K. A., Senbanjo, I. O., & Amole, O. O. (2009). Interns’ knowledge of clinical pharmacology and therapeutics after undergraduate and on-going internship training in Nigeria: a pilot study. BMC Medical Education, 9(50), 1–9. https://doi.org/10.1186/1472-6920-9-50

Parker, R. B., Rodgers, J. E., & Cavallari, L. H. (2008). Pharmacotherapy a pathophysiologic approach. In J. T. Dipiro, R. L. Talbert, G. C. Yee, G. R. Matzke, B. G. Wells, & L. M. Posey (Eds.), Pharmacotherapy A Pathophysiologic Approach (7th ed., pp. 173–212). The McGraw-Hill Companies, Inc. https://doi.org/10.1036/007147899X

Ponikowski, P., Voors, A. A., Anker, S. D., Bueno, H., Cleland, J. G. F., Coats, A. J. S., Falk, V., Gonzalez-Juanatey, J. R., Harjola, V.-P., Jankowska, E. A., Jessup, M., Linde, C., Nihoyannopoulos, P., Parissis, J. T., Pieske, B., Riley, J. P., Rosano, G. M. C., Ruilope, L. M., Ruschitzka, F., … Meer, P. van der. (2016). 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). European Heart Journal, 1–85. https://doi.org/10.1093/eurheartj/ehw128

Rascati, K. (2014). Essentials of pharmacoeconomics (2nd ed.). Lippincott Williams & Wilkins.

Syahidah, H. (2017). Kualitas hidup pasien kanker yang menjalani kemoterapi di RSI Sultan Agung Semarang. Universitas Muhammadiyah.

Tangsatitkiat, W., & Sakthong, P. (2010). Thai version of the minnesota living with heart failure questionnaire: psychometric testing using a longitudinal design. Asian Biomedicine, 4(6), 877–884. https://doi.org/10.2478/abm-2010-0115

Teng, T. K., Tromp, J., Tay, W. T., Anand, I., Ouwerkerk, W., Chopra, V., Wander, G. S., Yap, J. J. L., MacDonald, M. R., Xu, C. F., Chia, Y. M., Shimizu, W., Richards, A. M., Voors, A., & Lam, C. S. (2018). Prescribing patterns of evidence-based heart failure pharmacotherapy and outcomes in the ASIAN-HF registry: a cohort study. The Lancet Global Health, 6, e1008–e1018. https://doi.org/10.1016/S2214-109X(18)30306-1

Upadhya, B., & Kitzman, D. W. (2017). Heart failure with preserved ejection fraction in older adult. Heart Failure Clinics, 13(3), 485–502. https://doi.org/10.1016/j.hfc.2017.02.005

WHO. (2007). Prevention of cardiovascular disease: pocket guidelines for assessment and management of cardiovascular risk. In World Health Organization. WHO Press.

WHO. (2020). Cardiovascular Diseases. World Health Organization.

Yaghoubi, A., Tabrizi, J., Mirinazhad, M., Azami, S., Naghavi-behzad, M., & Ghojazadeh, M. (2012). Quality of life in cardiovascular patients in Iran and factors affecting It: a systematic Review. Journal of Cardiovascular and Thoracic Research, 4(4), 95–101. https://doi.org/10.5681/jcvtr.2012.024

Downloads

Published

2021-03-31

Issue

Vol. 11 No. 1 (2021): Pharmaciana

Section

Clinical and Community Pharmacy

License

Authors who publish with Pharmaciana agree to the following terms:

  1. Authors retain copyright and grant the journal the right of first publication with the work simultaneously licensed under a Creative Commons Attribution License (CC BY-SA 4.0) that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal. 
  2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.